Insider Selling: Annexon, Inc. (NASDAQ:ANNX) EVP Sells 5,515 Shares of Stock

Annexon, Inc. (NASDAQ:ANNX - Get Free Report) EVP Dean Richard Artis sold 5,515 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $2.97, for a total value of $16,379.55. Following the transaction, the executive vice president now directly owns 83,814 shares in the company, valued at $248,927.58. This trade represents a 6.17 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Annexon Trading Down 0.7 %

Shares of NASDAQ:ANNX traded down $0.02 on Thursday, hitting $2.83. The company had a trading volume of 796,392 shares, compared to its average volume of 1,392,680. The stock has a market cap of $301.65 million, a price-to-earnings ratio of -2.70 and a beta of 1.07. The stock has a 50 day moving average price of $4.33 and a 200 day moving average price of $5.59. Annexon, Inc. has a 1-year low of $2.63 and a 1-year high of $8.40.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ANNX. Needham & Company LLC restated a "buy" rating and set a $16.00 target price on shares of Annexon in a report on Friday, November 15th. HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of Annexon in a research note on Tuesday, December 17th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Annexon in a research note on Friday, November 15th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Annexon currently has an average rating of "Buy" and an average price target of $15.80.

Institutional Trading of Annexon

Hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets acquired a new stake in Annexon during the fourth quarter worth approximately $59,000. CANADA LIFE ASSURANCE Co bought a new position in shares of Annexon during the fourth quarter worth approximately $77,000. E Fund Management Co. Ltd. lifted its holdings in Annexon by 36.0% during the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company's stock worth $79,000 after purchasing an additional 4,086 shares during the last quarter. Forefront Analytics LLC boosted its stake in Annexon by 56.8% in the 4th quarter. Forefront Analytics LLC now owns 16,433 shares of the company's stock valued at $84,000 after purchasing an additional 5,950 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new position in Annexon in the 4th quarter valued at $98,000.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.